Akcea Therapeutics’ volanesorsen will be available to eligible patients in the UK before it is officially licensed in the EU, having been granted entry to the country’s Early Access to Medicines Scheme.
Akcea Therapeutics has filed for FDA approval of volanesorsen. The Ionis Pharmaceuticals spinout sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome (FCS) to market in the U.S. next year.